Gattex (teduglutide) is an injection administered once daily that helps improve intestinal absorption of fluids and nutrients, reducing the frequency and volume of parenteral nutrition. It is the third FDA-approved drug to treat adults with SBS receiving nutritional support. Zorbtive (somatropin) and Nutrestore (glutamine) were approved in 2003 and 2004, respectively.
“Today’s approval expands the available treatment options for patients with this life-threatening condition,” said Victoria Kusiak, M.D., deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research, in the release. “Because Gattex may cause other serious health conditions, it is critical that patients and health care professionals understand the drug’s potential and known safety risks.”
Gattex is marketed by Bedminster, N.J.-based NPS Pharmaceuticals.
Related Articles on FDA Approvals:
EndoChoice Receives FDA Clearance for Water Bottle Cap Irrigation System
Avinger Receives FDA Clearance for Smaller, Longer Optical Coherence Tomography Catheter
Smiths Medical Receives FDA Clearance for Portex CorrectInject Safety System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
